QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NYSE:MCK

McKesson (MCK) Stock Forecast, Price & News

$438.12
-1.74 (-0.40%)
(As of 09/21/2023 ET)
Compare
Today's Range
$437.93
$442.12
50-Day Range
$402.40
$440.06
52-Week Range
$331.75
$444.80
Volume
840,294 shs
Average Volume
896,199 shs
Market Capitalization
$59.10 billion
P/E Ratio
16.34
Dividend Yield
0.57%
Price Target
$452.33

McKesson MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
3.2% Upside
$452.33 Price Target
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.46mentions of McKesson in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$18.57 M Sold Last Quarter
Proj. Earnings Growth
13.47%
From $27.17 to $30.83 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

56th out of 961 stocks

Drugs, Proprietaries, & Sundries Industry

4th out of 8 stocks


MCK stock logo

About McKesson (NYSE:MCK) Stock

McKesson Corporation is a prominent player in the healthcare industry, offering a wide range of supply chain management solutions, retail pharmacy services, community oncology and specialty care, and healthcare information technology. With a rich history dating back to 1833, McKesson has established itself as a leading provider of essential healthcare products and services, contributing to the well-being of patients and the efficiency of healthcare providers.

The company's mission is to improve care in every setting, one product, partner, and patient at a time. McKesson operates globally, with a significant presence in the United States, Europe, and Canada, serving a diverse customer base, including hospitals, pharmacies, physician offices, surgery centers, nursing homes, and home health care agencies.

McKesson's operations are organized into several segments. The U.S. Pharmaceutical segment, one of the company's key pillars, is pivotal in distributing a comprehensive range of pharmaceutical drugs, including branded, generic, specialty, biosimilar, and over-the-counter medications. It is a crucial link in the pharmaceutical supply chain, ensuring the timely delivery of essential drugs to pharmacies and healthcare facilities across the United States.

In addition to pharmaceutical distribution, McKesson provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. The company empowers healthcare providers to optimize their practices, enhance patient care and improve overall efficiency by offering financial, operational, and clinical solutions.

McKesson's International segment extends its reach beyond the United States, providing distribution and services to wholesale, institutional, and retail customers in European countries and Canada. This global presence enables the company to leverage its expertise and resources to support healthcare systems and deliver high-quality products and services to a broader market.

The Medical-Surgical Solutions segment focuses on supply distribution, logistics, and other services. By catering to healthcare providers such as physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies, McKesson ensures that critical medical supplies are readily available, enabling efficient and effective patient care.

McKesson's management team is composed of highly experienced professionals who bring a wealth of expertise and strategic vision to the company. Led by Chief Executive Officer and Director Brian Scott Tyler, the team is dedicated to driving McKesson's mission forward. Brian Scott Tyler has been influential in steering the company toward continued growth and success. Under his leadership, McKesson has focused on innovation, strategic partnerships, and operational excellence. With a deep understanding of the healthcare landscape, Tyler has led the company through various challenges and has positioned it as a trusted partner for healthcare providers worldwide.

McKesson has consistently delivered strong financial performance, reflecting its ability to navigate the complexities of the healthcare industry while adapting to changing market dynamics. The company has demonstrated robust revenue growth over the years, driven by its diversified portfolio of products and services.

McKesson operates within the broader healthcare industry, characterized by continuous innovation, regulatory complexities, and a focus on patient care. As one of the largest healthcare distributors, McKesson faces competition from both traditional and emerging players in the market. However, the company's extensive distribution network, strong relationships with healthcare providers, and comprehensive product and service offerings give it a competitive edge.

The healthcare industry is subject to various regulatory and political factors impacting market dynamics. Changes in healthcare policies, reimbursement structures, and drug pricing regulations can significantly affect McKesson's operations. However, the company's deep industry knowledge and expertise enable it to navigate these challenges effectively.

McKesson is well-positioned to capitalize on several growth opportunities in the healthcare industry. One key area of focus is expanding its healthcare information technology solutions. As the digital transformation of the healthcare sector continues, McKesson's investments in technology and data analytics enable it to provide advanced solutions that enhance patient care, optimize workflows and drive operational efficiencies.

While McKesson has a strong market position and a track record of success, it faces certain risks and challenges that should be considered. One significant risk is the evolving regulatory landscape, including changes in healthcare policies and drug pricing regulations. Compliance with these regulations can increase costs and impact the company's profitability.

Additionally, competitive pressures within the healthcare industry require McKesson to continually innovate and differentiate its offerings. The emergence of new market entrants and disruptive technologies could challenge the company's market share and profitability.

The COVID-19 pandemic also introduced unprecedented challenges to the healthcare industry. While the pandemic presented opportunities for McKesson to support the healthcare system with essential supplies and services, it also disrupted healthcare operations and supply chains.

To mitigate these risks, McKesson has implemented robust risk management strategies. The company maintains strong relationships with regulatory bodies, stays abreast of industry trends, and invests in innovation and technology to stay ahead of the competition.

MCK Price History

MCK Stock News Headlines

3 Low P/E Stock ETFs for Hungry Value Investors (MCK)
The price-to-earnings, or P/E ratio, is one of the most commonly used value measures. For these unique value ETFs, having a low P/E ratio is just the start.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio
5 Cash Cow Stocks to Buy Now
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
Is McKesson (MCK) a Stable Stock?
See More Headlines
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Company Calendar

Ex-Dividend for 7/3 Dividend
5/31/2023
Dividend Payable
7/03/2023
Last Earnings
8/02/2023
Ex-Dividend for 10/2 Dividend
8/31/2023
Today
9/21/2023
Dividend Payable
10/02/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Sector
Medical
CUSIP
58155Q10
Employees
51,000
Year Founded
1833

Price Target and Rating

Average Stock Price Forecast
$452.33
High Stock Price Forecast
$495.00
Low Stock Price Forecast
$416.00
Forecasted Upside/Downside
+3.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$3.56 billion
Pretax Margin
1.66%

Debt

Sales & Book Value

Annual Sales
$276.71 billion
Cash Flow
$32.67 per share
Book Value
($10.99) per share

Miscellaneous

Free Float
134,619,000
Market Cap
$59.10 billion
Optionable
Optionable
Beta
0.60

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Brian S. Tyler Ph.D.Mr. Brian S. Tyler Ph.D. (Age 56)
    CEO & Director
    Comp: $7.22M
  • Mr. Britt J. VitaloneMr. Britt J. Vitalone (Age 54)
    Exec. VP & CFO
    Comp: $3.04M
  • Ms. Nancy AvilaMs. Nancy Avila (Age 55)
    Exec. VP, Chief Information Officer & CTO
    Comp: $1.97M
  • Ms. Lori A. Schechter J.D.Ms. Lori A. Schechter J.D. (Age 61)
    Exec. VP, Chief Legal Officer & Gen. Counsel
    Comp: $2.6M
  • Ms. LeAnn B. Smith (Age 48)
    Exec. VP & Chief HR Officer
    Comp: $1.32M
  • Mr. Napoleon B. Rutledge Jr. (Age 51)
    Sr. VP, Controller & Chief Accounting Officer
  • Rachel Rodriguez
    VP of Investor Relations
  • Mr. Pete Slone
    Sr. VP of Corp. Public Affairs
  • Mr. Kirk Kaminsky
    Pres of The US Pharmaceutical & Specialty Solutions Bus.
  • Paul A. Smith
    Sr. VP of Taxes













MCK Stock - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.
View MCK analyst ratings
or view top-rated stocks.

What is McKesson's stock price forecast for 2023?

8 brokers have issued 1-year price targets for McKesson's stock. Their MCK share price forecasts range from $416.00 to $495.00. On average, they anticipate the company's stock price to reach $452.33 in the next year. This suggests a possible upside of 3.2% from the stock's current price.
View analysts price targets for MCK
or view top-rated stocks among Wall Street analysts.

How have MCK shares performed in 2023?

McKesson's stock was trading at $375.12 at the start of the year. Since then, MCK shares have increased by 16.8% and is now trading at $438.12.
View the best growth stocks for 2023 here
.

When is McKesson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our MCK earnings forecast
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $5.85 by $1.42. The company earned $74.48 billion during the quarter, compared to the consensus estimate of $70.28 billion. McKesson had a net margin of 1.32% and a negative trailing twelve-month return on equity of 252.54%. The firm's revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.83 EPS.
Read the conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson announced a quarterly dividend on Monday, July 24th. Investors of record on Friday, September 1st will be given a dividend of $0.62 per share on Monday, October 2nd. This represents a $2.48 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 31st. This is a positive change from the stock's previous quarterly dividend of $0.54.
Read our dividend analysis for MCK
.

Is McKesson a good dividend stock?

McKesson (NYSE:MCK) pays an annual dividend of $2.48 per share and currently has a dividend yield of 0.57%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.25%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MCK will have a dividend payout ratio of 8.04% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MCK.

What guidance has McKesson issued on next quarter's earnings?

McKesson issued an update on its FY24 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of $26.55-$27.35 for the period, compared to the consensus estimate of $26.63.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson Chief Executive Officer Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among the company's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.54%), State Street Corp (4.82%), Geode Capital Management LLC (1.84%), Northern Trust Corp (1.15%), Bank of New York Mellon Corp (1.10%) and The Manufacturers Life Insurance Company (0.90%). Insiders that own company stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Lori A Schechter, Lori A Schechter, Nancy Avila, Nancy Flores, Sundeep G Reddy, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends
.

How do I buy shares of McKesson?

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $438.12.

How much money does McKesson make?

McKesson (NYSE:MCK) has a market capitalization of $59.10 billion and generates $276.71 billion in revenue each year. The company earns $3.56 billion in net income (profit) each year or $26.81 on an earnings per share basis.

How many employees does McKesson have?

The company employs 51,000 workers across the globe.

Does McKesson have any subsidiaries?
The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More
How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The official website for the company is www.mckesson.com. The company can be reached via phone at (972) 446-4800, via email at investors@mckesson.com, or via fax at 415-983-8453.

This page (NYSE:MCK) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -